Background and purpose of the Tokyo Guidelines

Acute cholecystitis is one of the most common surgical emergencies related to gallstone disease. Because presentation varies from mild inflammation to life-threatening sepsis with organ failure, clinicians need a shared language for diagnosis and a structured way to judge severity so that decisions about timing of cholecystectomy, need for gallbladder drainage, level of care, and antibiotic strategy can be aligned with evidence and local resources.

The Tokyo Guidelines were developed by an international hepatobiliary consensus process to standardize how acute cholecystitis is defined and how sick a patient is within that diagnosis. The 2018 revision (TG18) reaffirmed the Tokyo Guidelines 2013 (TG13) diagnostic criteria and severity grading for acute cholecystitis after review of the literature through 2017: no substantive changes were made because multiple validation studies had already shown strong association between TG13 grades and outcomes such as mortality, length of stay, conversion to open surgery, and cost.

This article supports the CalcMD calculator, which walks through Grade III organ/system dysfunction first, then Grade II moderate disease features, and otherwise classifies the case as Grade I mild—mirroring the guideline logic clinicians use at the bedside.

Clinical picture: what acute cholecystitis represents

Acute cholecystitis is an inflammatory syndrome centered on the gallbladder, usually due to cystic duct obstruction by a gallstone (calculous disease), though acalculous variants occur in critically ill or postoperative patients. Typical features include right upper quadrant pain, tenderness, and systemic signs of inflammation such as fever or laboratory evidence of an acute-phase response. Imaging often shows gallbladder wall thickening, distension, pericholecystic fluid, or sonographic Murphy sign.

Because many other conditions—acute hepatitis, perforated viscus, pancreatitis, pneumonia with referred pain, and others—can mimic or overlap with acute cholecystitis, guidelines emphasize combining clinical, laboratory, and imaging information rather than relying on a single finding.

Diagnostic criteria in TG18 (TG13 schema)

TG18 uses a three-axis schema (A, B, and C) that forces explicit documentation of local inflammation, systemic inflammation, and (for a definite diagnosis) imaging support.

A — Local signs of inflammation

At least one of the following should be present when applying the diagnostic framework:

• Murphy sign (inspiratory arrest with palpation in the right upper quadrant during deep inspiration), including sonographic Murphy sign when ultrasound is performed by an experienced operator.
• Right upper quadrant mass, pain, or tenderness attributable to gallbladder inflammation.

Local findings anchor the process to the gallbladder region and help distinguish cholecystitis from isolated systemic illness without a focal biliary source.

B — Systemic signs of inflammation

At least one systemic marker supports an active inflammatory state:

• Fever or documented elevated body temperature.
• Elevated C-reactive protein (CRP), reflecting acute inflammation.
• Leukocytosis or otherwise abnormal white blood cell count consistent with infection or inflammation.

Systemic signs are nonspecific; they gain diagnostic weight when paired with local gallbladder findings and, for definite diagnosis, characteristic imaging.

C — Imaging findings characteristic of acute cholecystitis

Imaging may include ultrasound, CT, or MRI depending on availability and clinical context. Findings consistent with acute cholecystitis commonly include gallbladder distension, wall thickening, pericholecystic fluid or fat stranding, gallstones or sludge, and supportive signs such as a positive sonographic Murphy sign. The guideline’s intent is that imaging demonstrates an inflammatory gallbladder process, not merely incidental cholelithiasis without acute changes.

How criteria combine: suspected versus definite diagnosis

Within the TG13/TG18 diagnostic scheme:

• Suspected acute cholecystitis is suggested when there is at least one A criterion and at least one B criterion.
• Definite acute cholecystitis is supported when there is one A, one B, and imaging (C) characteristic of acute cholecystitis.

Clinicians should also exclude alternative diagnoses that can reproduce similar features, including acute hepatitis, other acute abdominal catastrophes, and chronic cholecystitis without an acute inflammatory picture, so that the diagnostic label matches the patient’s true process.

Severity grading: why it matters

Once acute cholecystitis is recognized, severity grading estimates how extensive inflammation is locally and systemically and whether the patient has crossed into organ dysfunction. TG18 management pathways use grade together with comorbidity measures (such as the Charlson Comorbidity Index) and ASA physical status to discuss timing of laparoscopic cholecystectomy versus initial medical therapy with or without gallbladder drainage and delayed surgery.

Validation work summarized in TG18 indicates that higher grades correlate with worse outcomes, which is why the same grading system has remained in place rather than being replaced by an unproven alternative.

Grade III — Severe acute cholecystitis (organ/system dysfunction)

Grade III is defined by dysfunction in any one of several major organ/system domains. The conceptual model parallels other TG organ-failure definitions used in hepatobiliary emergencies: if the patient has shock needing vasopressors, obtundation, severe hypoxemia, renal injury, coagulopathy reflecting hepatic synthetic failure, or critical thrombocytopenia, the disease is severe regardless of how “localized” the gallbladder looks on imaging.

Practical implications include escalation to intensive monitoring, aggressive resuscitation, broad-spectrum antibiotics, early specialist involvement, and thoughtful sequencing of source control (cholecystectomy versus percutaneous or endoscopic drainage strategies) based on physiology, anatomy, and center capability.

When following full TG18 flowcharts, clinicians also integrate additional variables such as total bilirubin in specific branches; the calculator focuses on the published organ-dysfunction list but users should still apply complete pathway elements from the primary guideline sources in real practice.

Grade II — Moderate acute cholecystitis

If no Grade III organ dysfunction is present, the patient may still have moderate (Grade II) acute cholecystitis when any one of the following is true. This is a key distinction from acute cholangitis grading in the Tokyo system, where moderate disease uses a different rule set.

• Marked leukocytosis with white blood cell count greater than 18,000/mm³, reflecting an intense systemic inflammatory response.
• Palpable tender mass in the right upper quadrant, often corresponding to a distended, inflamed gallbladder or phlegmonous change.
• Prolonged symptom duration with complaints lasting more than 72 hours, which is associated with more difficult dissection, higher conversion risk, and greater local inflammatory complexity in many series.
• Marked local inflammation on imaging or clinically, including advanced patterns such as gangrenous cholecystitis, pericholecystic abscess, hepatic abscess, biliary peritonitis, or emphysematous cholecystitis—entities that imply tissue necrosis, gas-forming infection, or spread beyond the gallbladder fossa.

Moderate grade should prompt careful operative planning, surgeon experience considerations, and heightened vigilance for progression to organ failure.

Grade I — Mild acute cholecystitis

Grade I (mild) applies when the patient does not meet Grade III and does not meet Grade II. In teaching terms, this is often described as acute cholecystitis without organ dysfunction and without the high-risk local or systemic markers that define moderate disease—circumstances where early laparoscopic cholecystectomy is typically feasible in appropriately selected patients, assuming comorbidity and overall risk are acceptable.

Mild grade does not mean “optional treatment”; it means the inflammatory phenotype, as classified by TG criteria, is less advanced than in higher grades.

How the CalcMD calculator applies the rules

The interactive tool is designed to mirror guideline sequencing:

1. Review Grade III organ/system dysfunction items. If any are present, severity is Grade III regardless of gallbladder-specific findings.
2. If none are present, review Grade II moderate criteria. If any one or more are present, severity is Grade II.
3. If neither block is satisfied, severity is Grade I.

The output summarizes the assigned grade and offers high-level clinical orientation consistent with TG18 themes (timing of cholecystectomy versus drainage, monitoring for deterioration, multidisciplinary input). It does not replace complete pathway diagrams, institutional protocols, or bedside judgment.

Dynamic assessment and documentation

Severity is not a single snapshot frozen at triage. After intravenous fluids, antibiotics, and analgesia, leukocyte counts, hemodynamics, and mental status may improve or worsen. Re-evaluation is essential when a patient who initially appeared mild develops hypotension, new oxygen requirements, rising creatinine, coagulopathy, or refractory pain suggesting perforation or necrosis.

Documenting which A/B/C elements supported the diagnosis and which severity criteria were met improves communication among emergency medicine, surgery, gastroenterology, radiology, and critical care teams—especially during handoffs and transfer between facilities.

Clinical and educational notice: This article and the associated calculator summarize publicly described TG18/TG13 criteria for learning and decision support. They are not a substitute for reading the full guideline, local policies, or individualized medical advice.